mRNA vaccines have brought about a great revolution in the vaccine fields owing to their
simplicity and adaptability in antigen design, potential to induce both humoral and cell …

Neutralizing antibodies (nAbs) are being increasingly used as passive antiviral reagents in
prophylactic and therapeutic modalities and to guide viral vaccine design. In vivo, nAbs can …

Despite vaccine availability, influenza remains a substantial global public health concern.
Here, we report interim findings on the primary and secondary objectives of the safety …

Members of the coronaviridae family are endemic to human populations and have caused
several epidemics and pandemics in recent history. In this review, we will discuss the …

Human broadly neutralizing antibodies (bnAbs) targeting the hemagglutinin stalk of group 1
influenza A viruses (IAVs) are biased for IGHV1-69 alleles that use phenylalanine (F54) but …

Influenza viruses usually cause seasonal influenza epidemics and influenza pandemics,
resulting in acute respiratory illness and, in severe cases, multiple organ complications and …

Influenza viruses have perplexed scientists for over a hundred years. Yearly vaccines limit
their spread, but they do not prevent all infections. Therapeutic treatments for those …

Influenza A virus (IVA) has been continuously causing pandemics in several animal hosts
and has become a worldwide public health threat. Currently, antiviral drugs have become …

CD4+ follicular regulatory T (Tfr) cells control B cell responses through the modulation of
follicular helper T (Tfh) cells and germinal center development while suppressing …

Universal influenza vaccines should protect against continuously evolving and newly
emerging influenza viruses. T cells may be an essential target of such vaccines, as they can …